News | April 09, 2026
OPPI and NIPER Raebareli partner to boost pharma research and talent
Scholarships, research grants and industry mentorship framework aim to strengthen India’s pharma R&D ecosystem
Scholarships, research grants and industry mentorship framework aim to strengthen India’s pharma R&D ecosystem
Both ordinary resolutions sail through with over 99.6% votes in favour, strengthening leadership continuity at the drugmaker
API maker begins circulation of second and final call money notice for partly paid-up rights shares, completing the last leg of its 2024 fundraising cycle
Immediate U.S. launch planned for dapagliflozin-metformin ER tablets; addressable market estimated at $514 millionannually
The acquisition aims to bolster Merck’s hematology portfolio with Terns’ lead oncology candidate, TERN-701
The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline
Multi-year CDMO partnership combines AI-led virtual development, precision chemistry and GMP manufacturing to accelerate five high-science APIs across regulated markets
Final approval for diabetes and heart-failure drug opens access to a $10.5 billion US market opportunity, with shared exclusivity benefits.
Board approves five-year appointment, subject to shareholder nod through postal ballot
The company has highlighted setbacks in Phase II studies while outlining fresh regulatory and late-stage development plans for Fibromun and Nidlegy
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
